Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

54.85USD
6 Dec 2019
Change (% chg)

$1.09 (+2.03%)
Prev Close
$53.76
Open
$55.86
Day's High
$57.02
Day's Low
$54.07
Volume
275,844
Avg. Vol
180,680
52-wk High
$67.86
52-wk Low
$29.17

Select another date:

Fri, Dec 6 2019

Photo

Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.

UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Dec 6 Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.

Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Dec 6 Biohaven Pharmaceutical said on Friday it would continue with a late-stage study of its experimental Alzheimer's treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results.

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

July 19 Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

Select another date: